ChinaHealthcare and life sciences2025 – ongoingCSPC Pharmaceutical Group Limited
AI-assisted drug discovery platform
CSPC linked its AI drug-discovery platform to 3 small-molecule licensing agreements
Problem
Drug discovery required long development cycles and substantial spending, with low clinical success rates. CSPC sought to reduce the experimental work needed to identify candidates.
Approach
CSPC combined external partnerships with internal development to build an AI-assisted discovery platform. It supported target discovery and molecule generation, alongside structure and ADMET prediction. The company described its use from initial screening through clinical development.
Results
Takeaway
CSPC attributed licensing agreements to the platform, but did not quantify its contribution relative to laboratory research or disclose measured development-time savings.
Categories
- Size
- Large enterprise
- Industry
- Healthcare and life sciences
- Business function
- IT and R&D
- Innovation type
- Process innovation
- AI technology
- Generative AIPredictive analytics and ML
- Adoption
- Partner co-development
- Evidence
- Company's own claim
Sources
Source summaries
CSPC described an operational AI-assisted drug-discovery platform developed through partnerships and internal work. It attributed 3 small-molecule licensing agreements in the preceding year to the platform without separating AI's contribution from other research.
Full details are in the original sources.